VanEck Pharmaceutical ETF
148 hedge funds and large institutions have $789M invested in VanEck Pharmaceutical ETF in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 42 reducing their positions, and 24 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
1% more funds holding
Funds holding: 146 → 148 (+2)
2% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 42
6% less capital inflows, than outflows
Capital inflows: $337M | Capital outflows: $357M
7.8% less ownership
Funds ownership: 68.62% → 60.82% (-7.8%)
95% less call options, than puts
Call options by funds: $603K | Put options by funds: $11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$86.4M |
| 2 |
Employees Retirement System of Texas
Austin,
Texas
|
+$56.6M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$34.4M |
| 4 |
Tower Research Capital (TRC)
New York
|
+$31.5M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$26.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$118M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$53.2M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$50M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$42.1M |
| 5 |
Clal Insurance
Tel-Aviv,
Israel
|
-$33.5M |
PPH Hedge Fund Activity: Q1 2026 in Review
148 of the 8,210 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2026, worth a combined $789M — down 2.1% from $806M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PPH positions and 24 closed out — a net gain of 5 holders — while 41 added to existing stakes and 42 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $86.4M. The largest seller was Citigroup, cutting an estimated $118M.
- 148 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2026, up from 146 in Q4 2025.
- Funds reported $789M of VanEck Pharmaceutical ETF stock for Q1 2026, down 2.1% quarter-over-quarter.
- 29 funds opened new VanEck Pharmaceutical ETF positions in Q1 2026 and 24 closed out, a net change of +5 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2026 was Jane Street, an estimated $86.4M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2026 was Citigroup, an estimated $118M sold.
Based on aggregated 13F filings for Q1 2026.